- Home
- WBX vs CTSO Comparison
WBX vs CTSO Comparison
Compare WBX & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WBX
- CTSO
- Stock Information
- Founded
- WBX 2015
- CTSO 1997
- Country
- WBX Spain
- CTSO United States
- Employees
- WBX N/A
- CTSO N/A
- Industry
- WBX Industrial Specialties
- CTSO Medical/Dental Instruments
- Sector
- WBX Consumer Discretionary
- CTSO Health Care
- Exchange
- WBX Nasdaq
- CTSO Nasdaq
- Market Cap
- WBX 76.3M
- CTSO 72.8M
- IPO Year
- WBX N/A
- CTSO N/A
- Fundamental
- Price
- WBX $3.93
- CTSO $0.94
- Analyst Decision
- WBX Buy
- CTSO Buy
- Analyst Count
- WBX 4
- CTSO 2
- Target Price
- WBX $10.50
- CTSO $5.50
- AVG Volume (30 Days)
- WBX 19.9K
- CTSO 380.5K
- Earning Date
- WBX 07-31-2025
- CTSO 08-07-2025
- Dividend Yield
- WBX N/A
- CTSO N/A
- EPS Growth
- WBX N/A
- CTSO N/A
- EPS
- WBX N/A
- CTSO N/A
- Revenue
- WBX $173,788,608.00
- CTSO $36,107,520.00
- Revenue This Year
- WBX N/A
- CTSO $11.93
- Revenue Next Year
- WBX $46.25
- CTSO $21.22
- P/E Ratio
- WBX N/A
- CTSO N/A
- Revenue Growth
- WBX N/A
- CTSO 20.18
- 52 Week Low
- WBX $4.05
- CTSO $0.71
- 52 Week High
- WBX $30.00
- CTSO $1.61
- Technical
- Relative Strength Index (RSI)
- WBX 43.33
- CTSO 45.64
- Support Level
- WBX $4.22
- CTSO $0.85
- Resistance Level
- WBX $4.50
- CTSO $0.99
- Average True Range (ATR)
- WBX 0.27
- CTSO 0.08
- MACD
- WBX -0.08
- CTSO -0.01
- Stochastic Oscillator
- WBX 4.85
- CTSO 28.95
About WBX Wallbox N.V.
Wallbox NV is a smart electric vehicle charging and energy management company. It creates a smart charging system combining technology design that manages the communication between the user, vehicle, grid, building, and charger. The company designs, manufactures, and distributes faster, simpler EV charging solutions for residential, business, and public use. Its smart charging product portfolio includes Level 2 alternating current chargers for home and business applications and direct current fast chargers for public applications. The company has three reportable operating segments; Europe, Middle East and Asia (EMEA), its key revenue-generating segment, North America, and Asia-Pacific.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.